2009 Pre-Interphex Showcase: Information Technology

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Teva’s investigational monoclonal antibody, TEV-53408, has been designed for use in adults with celiac disease, for which a strict and lifelong gluten-free diet is currently the only treatment.

Companies Reveal Their Next Moves in Manufacturing

In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.

A lab technician in protective gear operates a tablet displaying a green checkmark in a high-tech pharmaceutical laboratory. | Image Credit: © greenbutterfly - stock.adobe.com

Transformations in Drug Development for Cell and Gene Therapies

In discussions at INTERPHEX 2025, company representatives seized upon several common themes, most notably safety, sustainability, and the increasing utility of automation.

PPD;Thermo Fisher Scientific

March 28th 2025

End-to-end regulatory CDMO solutions: development, manufacturing, and approval (May 2025)

As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.

Exploring the need for dose-flexible manufacturing

FDA Grants Fast Track Designation to Teva Celiac Disease Candidate

Related Content

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Teva’s investigational monoclonal antibody, TEV-53408, has been designed for use in adults with celiac disease, for which a strict and lifelong gluten-free diet is currently the only treatment.

Companies Reveal Their Next Moves in Manufacturing

Transformations in Drug Development for Cell and Gene Therapies

In discussions at INTERPHEX 2025, company representatives seized upon several common themes, most notably safety, sustainability, and the increasing utility of automation.

PPD;Thermo Fisher Scientific

March 28th 2025

End-to-end regulatory CDMO solutions: development, manufacturing, and approval (May 2025)

Exploring the need for dose-flexible manufacturing